

an international reproductive health journal

Contraception

Volume 88, Number 3, September 2013

Publication information: *Contraception* (ISSN 0010-7824) is published monthly by Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710. Periodicals postage paid at New York, NY, and additional mailing offices.

USA POSTMASTER: Send address changes to *Contraception*, Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA.

Annual subscription rates: United States and possessions: individual, \$434; institution, \$1,383. All other countries: individual, \$478; institution, \$1,456.

Orders, claims, and journal inquiries: Please contact the Elsevier Customer Service Department nearest you: **St. Louis:** Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA; phone: (800) 654-2452 [toll free within the USA]; (+1) (314) 447-8871 [outside the USA]; fax: (+1) (314) 447-8029; e-mail: JournalCustomerService-usa@elsevier.com. **Oxford:** Elsevier Customer Service Department, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) (1865) 843434; fax: (+44) (1865) 843970; e-mail: JournalsCustomerServiceEMEA@elsevier.com. **Tokyo:** Elsevier Customer Service Department, 4F Higashi-Azabu, 1-Chome Bldg, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: JournalsCustomerServiceJapan@elsevier.com. **Singapore:** Elsevier Customer Service Department, 3 Killiney Road, #08-01 Winsland House I, Singapore 239519; phone: (+65) 63490222; fax: (+65) 67331510; e-mail: JournalsCustomerServiceAPAC@elsevier.com.

Advertising information: Advertising orders and inquiries can be sent to: USA, Canada and South America: Le-Andrea Sylvester, Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710, Tel.: (212) 633-3649, e-mail: le.sylvester@elsevier.com.

Reprints: To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710; E-mail: reprints@elsevier.com.

Author information: For full and complete Author Information, please go to: <http://www.contraceptionjournal.org/authorinfo>.

Author inquiries: For inquiries relating to the submission of articles (including electronic submission), please visit this journal's homepage at www.elsevier.com/locate/issn/0010-7824. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted articles at <http://www.elsevier.com/trackarticle>. You can also check our Author FAQs at <http://www.elsevier.com/authorFAQ> and/or contact Customer Support via <http://support.elsevier.com>.

Funding body agreements and policies: Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit: <http://www.elsevier.com/fundingbodies>.

© 2013 by Elsevier Inc. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Inc., and the following terms and conditions apply to their use:

Photocopying: Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK)/(+1) 215 239 3804 (USA).

Derivative Works: Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions).

Electronic Storage or Usage: Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article (please consult www.elsevier.com/permissions). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher.

Notice: No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

∞™ This paper meets the requirements of ANSI Standard Z39.48-1992 (Permanence of Paper).

Editorial

- 319** Featured Research at the 2013
North American Forum on Family Planning
Carolyn Westhoff, Lawrence Finer, Stephanie Teal

- ARHP Commentary—Thinking (Re)Productively**
321 Delivering on MPTs: Addressing the Needs, Rising to the Challenges and Making the Opportunities
R. Karl Malcolm, Susan M. Fetherston

Commentaries

- 326** Controversies in Family Planning: Arteriovenous Malformation
Jennifer A. Russo, Laura Gil, Teresa DePiñeres
- 330** Controversies in Family Planning: Desired Pregnancy, IUD In Situ and No Strings Visible
Carter Owen, Stephanie Sober, Courtney A. Schreiber
- 334** Surgical Aspects of Removal of Essure Microinsert
Catherine M. Albright, Gary N. Frishman, Bala Bhagavath
- 337** Antenatal Contraception — Simple, Feasible, But is It Safe and Ethical in Resource-Poor Environments?
Rudiger Pittrof, Veronique Filippi, Der Adolphe Somé, Georges Compaore, Nicolas Meda

Clinical Guidelines

- 341** Interruption of Nonviable Pregnancies of 24–28 Weeks' Gestation Using Medical Methods
Jamila B. Perritt, Anne Burke, Alison B. Edelman

Review Article

- 350** A Review of Evidence for Safe Abortion Care
Nathalie Kapp, Patti Whyte, Jennifer Tang, Emily Jackson, Dalia Brahma

Original Research Articles

- 364** Effect of a New Oral Contraceptive With Estradiol Valerate/Dienogest on Carbohydrate Metabolism
Vincenzo De Leo, Franca Fruzzetti, Maria Concetta Musacchio, Valeria Scolaro, Alessandra Di Sabatino, Giuseppe Morgante

(Continued)

(Contents continued)

- 369** Effect of a Contraceptive Pill Containing Estradiol Valerate and Dienogest (E2V/DNG) in Women With Menstrually-Related Migraine (MRM)
Rossella E. Nappi, Erica Terreno, Grazia Sances, Ellis Martini, Silvia Tonani, Valentina Santamaria, Cristina Tassorelli, Arsenio Spinillo
- 376** “We Never Thought of a Vasectomy”: A Qualitative Study of Men and Women’s Counseling Around Sterilization
Grace Shih, Kate Dubé, Christine Dehlendorf
- 382** Effect of Topical Vaginal Products on the Detection of Prostate-Specific Antigen, a Biomarker of Semen Exposure, Using ABACards
Margaret C. Snead, Athena P. Kourtis, Carolyn M. Black, Christine K. Mauck, Teresa M. Brown, Ana Penman-Aguilar, Johan H. Melendez, Maria F. Gallo, Denise J. Jamieson, Maurizio Macaluso
- 387** TSPY4 is a Novel Sperm-Specific Biomarker of Semen Exposure in Human Cervicovaginal Fluids; Potential Use in HIV Prevention and Contraception Studies
Terry A. Jacot, Irina Zalenskaya, Christine Mauck, David F. Archer, Gustavo F. Doncel
- 396** Women’s Questions After Postabortion Insertion of Intrauterine Contraception
Justin T. Diedrich, Eleanor A. Drey, Christine Dehlendorf, Jody E. Steinauer
- 401** Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate by Adolescent Women
Rebekah L. Williams, Devon J. Hensel, J. Dennis Fortenberry
- 408** Examining the Role of Oral Contraceptive Users as an Experimental and/or Control Group in Athletic Performance Studies
Kirsty Jayne Elliott-Sale, Stephanie Smith, James Bacon, David Clayton, Martin McPhilimey, Georgios Goutianos, Jennifer Hampson, Craig Sale
- 413** Combined Oral Contraceptive Containing Drospirenone Does Not Modify 24-H Ambulatory Blood Pressure But Increases Heart Rate in Healthy Young Women: Prospective Study
Angelo Cagnacci, Serena Ferrari, Antonella Napolitano, Ilaria Piacenti, Serenella Arangino, Annibale Volpe

(Continued)

(Contents continued)

- 418** Effects of Progestin-Only Long-Acting Contraception on Metabolic Markers in Obese Women
Nicole M. Bender, Penina Segall-Gutierrez, Sandy Oliver Lopez Najera, Frank Z. Stanczyk, Martin Montoro, Daniel R. Mishell Jr.
- 426** Characteristics of Scheduled Bleeding Manipulation With Combined Hormonal Contraception in University Students
Hannah Lakehomer, Paul F. Kaplan, David G. Wozniak, Christopher T. Minson
- 431** **Letters to the Editor**
- Abstracts**
- 433** *North American Forum on Family Planning Scientific Abstracts*
Seattle, Washington, October 6–7, 2013